Analysts Set Dicerna Pharmaceuticals Inc (DRNA) PT at $21.31

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) has been assigned a consensus recommendation of “Buy” from the twelve ratings firms that are currently covering the stock, MarketBeat reports. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $21.31.

Several equities research analysts have recently issued reports on DRNA shares. BidaskClub raised Dicerna Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 23rd. Leerink Swann started coverage on Dicerna Pharmaceuticals in a report on Tuesday, November 27th. They issued an “outperform” rating and a $24.00 target price on the stock. B. Riley lifted their target price on Dicerna Pharmaceuticals from $10.00 to $13.50 and gave the stock a “neutral” rating in a report on Monday, September 17th. Citigroup started coverage on Dicerna Pharmaceuticals in a report on Thursday, September 13th. They issued a “buy” rating and a $27.00 target price on the stock. Finally, Chardan Capital reaffirmed a “hold” rating and issued a $14.50 target price on shares of Dicerna Pharmaceuticals in a report on Monday, August 13th.

NASDAQ:DRNA traded down $1.22 on Monday, reaching $12.74. 393,271 shares of the company’s stock traded hands, compared to its average volume of 351,365. The stock has a market cap of $875.74 million, a PE ratio of -3.48 and a beta of 2.39. Dicerna Pharmaceuticals has a 12 month low of $6.80 and a 12 month high of $17.98.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its quarterly earnings results on Monday, November 5th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($0.11). Dicerna Pharmaceuticals had a negative net margin of 1,418.01% and a negative return on equity of 63.24%. The business had revenue of $1.55 million for the quarter, compared to the consensus estimate of $1.67 million. As a group, research analysts forecast that Dicerna Pharmaceuticals will post -1.15 EPS for the current year.

In other news, Director Brian K. Halak sold 564,300 shares of Dicerna Pharmaceuticals stock in a transaction dated Thursday, November 1st. The stock was sold at an average price of $13.66, for a total value of $7,708,338.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Brian K. Halak sold 335,000 shares of Dicerna Pharmaceuticals stock in a transaction dated Tuesday, November 6th. The stock was sold at an average price of $13.33, for a total value of $4,465,550.00. The disclosure for this sale can be found here. Insiders sold 1,144,396 shares of company stock worth $15,585,624 over the last ninety days. Insiders own 19.85% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. State Board of Administration of Florida Retirement System purchased a new position in Dicerna Pharmaceuticals in the second quarter worth about $178,000. Metropolitan Life Insurance Co. NY purchased a new position in Dicerna Pharmaceuticals in the second quarter worth about $188,000. Voya Investment Management LLC purchased a new position in Dicerna Pharmaceuticals in the second quarter worth about $208,000. MetLife Investment Advisors LLC purchased a new position in Dicerna Pharmaceuticals in the second quarter worth about $266,000. Finally, BlueMountain Capital Management LLC purchased a new position in Dicerna Pharmaceuticals in the second quarter worth about $331,000. Institutional investors own 87.20% of the company’s stock.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia.

See Also: Stock Symbols Definition, Examples, Lookup

Analyst Recommendations for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply